Πέμπτη 16 Νοεμβρίου 2017

NICE recommends routine NHS funding for new breast cancer drugs

The new breast cancer drugs palbociclib (Ibrance, Pfizer) and ribociclib (Kisqali, Novartis) should be routinely funded on the NHS, draft guidance from the National Institute for Health and Care...
recent?d=yIl2AUoC8zA recent?d=dnMXMwOfBR0 recent?i=fwNZFVoMUcw:b3CgNTeFECk:V_sGLiP recent?d=qj6IDK7rITs recent?i=fwNZFVoMUcw:b3CgNTeFECk:gIN9vFw recent?d=l6gmwiTKsz0 recent?d=7Q72WNTAKBA recent?i=fwNZFVoMUcw:b3CgNTeFECk:F7zBnMy recent?i=fwNZFVoMUcw:b3CgNTeFECk:-BTjWOF


from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2jwyAVV
via IFTTT

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου

Δημοφιλείς αναρτήσεις